3D Medicines Narrows Loss in H1 as Revenue Edges Up
MT Newswires Live
Sep 01
3D Medicines (HKG:1244) narrowed its attributable loss to 89.4 million yuan in the first half of 2025 from 103.5 million yuan a year prior, an Aug. 29 Hong Kong bourse filing said.
Shares of the biopharmaceutical company were down nearly 3% in Monday afternoon trading.
Loss per share was 0.36 yuan, down from 0.42 yuan in the year-ago period.
Revenue for the interim period jumped 1.3% to 209.2 million yuan from 206.4 million yuan in the corresponding period of the last year, mainly due to a stable sales revenue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.